Author: XtalPi

XtalPi integrates quantum physics and AI to create computational drug discovery and development applications that accurately predict important drug properties of small molecules, helping researchers accelerate and de-risk pharmaceutical innovations.

XtalPi announces the closing of $46 million Series B-1 extension to drive growth and accelerate platform development

CAMBRIDGE, Mass., Oct 24, 2018 – XtalPi Inc, a computation-driven biotech startup integrating quantum physics, artificial intelligence (AI), and cloud computing to empower pharmaceutical research, today announced a Series B-1 extension financing of $46 million to support XtalPi’s continuous market growth and expand the application...

Read More

XtalPi Inc. Announces Strategic Research Collaboration with Pfizer Inc. to Develop Artificial Intelligence-Powered Molecular Modeling Technology for Drug Discovery

CAMBRIDGE, Mass., May 8, 2018 –XtalPi Inc. (“XtalPi”), a computation-driven pharmaceutical technology company, announced today a strategic research collaboration with Pfizer Inc. (NYSE:PFE) (“Pfizer”) to develop a hybrid physics- and artificial intelligence (AI)-powered software platform for accurate molecular modeling of drug-like small molecules.   This state-of-the-art platform...

Read More

XtalPi and AMRI’s SSCI Enter into Joint Research Agreement to Apply Computational Technologies to Solid-Form Pharmaceutical Research Challenges

  Boston, Mass., (July 21, 2017) –XtalPi Inc., a pharmaceutical technology company offering intelligent digital drug development solutions to empower more efficient pharmaceutical research, is joining forces with AMRI SSCI, LLC (SSCI), a division of Albany Molecular Research, Inc. (AMRI), to identify solid forms of small...

Read More